Eli Lilly | LLY - Equity Capital And Reserves


Eli Lilly reported $40.27B in Equity Capital and Reserves for its fiscal quarter ending in September of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -4.58B 1.35B Sep/2026
Abbott USD 51.03B 83M Sep/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Amgen USD 14.35B 2.66B Sep/2026
AstraZeneca USD 51.73B 1.43B Sep/2026
Baxter International USD 6.5B 296M Sep/2026
Biogen USD 19.04B 194.3M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Drreddys Laboratories INR 389.37B 8.91B Sep/2026
Eli Lilly USD 40.27B 6.39B Sep/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
GlaxoSmithKline GBP 18.75B 1.11B Sep/2026
Glaxosmithkline GBP 18.36B 940M Sep/2026
J&J USD 81.53B 3.44B Sep/2026
Medtronic USD 50.23B 160M Jun/2026
Merck USD 44.89B 2.96B Sep/2026
Neurocrine Biosciences USD 3.88B 185.1M Sep/2026
Novartis USD 37.23B 4.72B Sep/2026
Novartis USD 37.56B 1.36B Sep/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Perrigo USD 2.44B 75.4M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Phibro Animal Health USD 417.67M 32.19M Sep/2026
Prestige Brands USD 1.94B 27.95M Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 72.88B 3.31B Sep/2026
Sanofi EUR 69.57B 3.58B Jun/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Zoetis USD 3.3B 155M Sep/2026